Literature DB >> 23212125

Dental risk factors for osteonecrosis of the jaws: a CONDOR case-control study.

A Barasch1, J Cunha-Cruz, F Curro, T DeRouen, G H Gilbert, P Hujoel, M M Safford, D A Vena, A E Voinea-Griffin, H Wu.   

Abstract

BACKGROUND: Reports of osteonecrosis of the jaw (ONJ) have associated this lesion to treatment with bisphosphonates (BPs) and dental procedures. In this study, we investigated the association of specific dental diagnoses and procedures with ONJ among patients with past BP use.
METHODS: Dentists from three practice-based research networks provided ONJ cases and controls (1:3). Data gathered from patients and dental offices with two respective standard questionnaires included demographic, medical, pharmaceutical, and dental information. Diagnoses and procedures up to 3 years prior to ONJ (prior to interview for controls) were analyzed within risk strata, defined by BP use and cancer status, using interaction terms within conditional logistic regression models.
RESULTS: We enrolled 191 ONJ cases and 573 controls from 119 dental offices. Among participants who had used only oral BP, extraction was the only dental risk factor for ONJ (odds ratio (OR) = 12, p = 0.01). Suppuration was also more prevalent in cases (18 %) than in controls (9 %), but not statistically significant (OR = 9, p = 0.06). Among participants who had not used either oral or IV BP (a majority of whom received radiation therapy to the head and neck), suppuration was the only dental risk factor for ONJ (prevalence = 34 % for cases and 8 % for controls; OR = 7, p = 0.01). The prevalence of extractions in this group was also higher, but not statistically significant (44 vs 10 %; OR = 3). Limited power precludes definitive findings among participants exposed to IV BP.
CONCLUSIONS: Among patients taking oral BP, extraction was the only dental procedure associated with subsequent ONJ development CLINICAL RELEVANCE: Results of this study suggest that routine dental procedures are not associated with development of ONJ in patients exposed to BPs.

Entities:  

Mesh:

Year:  2012        PMID: 23212125      PMCID: PMC3594331          DOI: 10.1007/s00784-012-0880-4

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  23 in total

1.  Bisphosphanates and oral cavity avascular bone necrosis.

Authors:  Cesar A Migliorati
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

2.  Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Sara Galluzzo; Fabrizio Battistoni; Laura Rocci; Olga Venditti; Gaia Schiavon; Silvia Angeletti; Federica Uzzalli; Michele Caraglia; Giordano Dicuonzo; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

3.  Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.

Authors:  E Merigo; M Manfredi; M Meleti; D Corradi; P Vescovi
Journal:  J Oral Pathol Med       Date:  2005-11       Impact factor: 4.253

4.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

5.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

Review 6.  Pathogenesis and natural history of osteonecrosis.

Authors:  Yehudith Assouline-Dayan; Christopher Chang; Adam Greenspan; Yehuda Shoenfeld; M Eric Gershwin
Journal:  Semin Arthritis Rheum       Date:  2002-10       Impact factor: 5.532

7.  Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

Authors:  Pierrick Fournier; Sandrine Boissier; Stéphanie Filleur; Julien Guglielmi; Florence Cabon; Marc Colombel; Philippe Clézardin
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

8.  Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

Authors:  Torsten Hansen; Martin Kunkel; Achim Weber; C James Kirkpatrick
Journal:  J Oral Pathol Med       Date:  2006-03       Impact factor: 4.253

Review 9.  Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

Authors:  Sook-Bin Woo; John W Hellstein; John R Kalmar
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

10.  Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. a pilot study.

Authors:  Maria Stella Moreira; Emilio Katayama; Antonio Carlos Bombana; Márcia Martins Marques
Journal:  Dent Traumatol       Date:  2005-12       Impact factor: 3.333

View more
  4 in total

Review 1.  Appropriate and necessary oral care for people with cancer: guidance to obtain the right oral and dental care at the right time.

Authors:  Joel B Epstein; Pelin Güneri; Andrei Barasch
Journal:  Support Care Cancer       Date:  2014-03-28       Impact factor: 3.603

2.  The association with xerostomia from sialadenitis and the jaw osteonecrosis in head and neck cancer population: a nationwide cohort study.

Authors:  Yi-Fang Huang; Chih-Hsin Muo; Chun-Hao Tsai; Shih-Ping Liu; Chung-Ta Chang
Journal:  Clin Oral Investig       Date:  2018-05-03       Impact factor: 3.573

Review 3.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

Review 4.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.